TCR2 Therapeutics
Seite 1 von 3 Neuester Beitrag: 02.06.23 21:28 | ||||
Eröffnet am: | 09.01.21 23:27 | von: RichyBerlin | Anzahl Beiträge: | 51 |
Neuester Beitrag: | 02.06.23 21:28 | von: iTechDachs | Leser gesamt: | 18.995 |
Forum: | Börse | Leser heute: | 34 | |
Bewertet mit: | ||||
Seite: < | 2 | 3 > |
Aber auch ein Sinnbild dafür, wie wenig Beachtung TCR-Therapien in Deutschland finden.
Hier aktuelle News;
TCR² Therapeutics Announces 2021 Strategic Priorities and Milestones
Published: Jan 08, 2021
- Additional data from ongoing gavo-cel Phase 1/2 trial to be presented in 1H21
- Identification of gavo-cel recomm. Phase 2 dose and initiation of Phase 2 study expected in 2021
- Initial data from ongoing TC-110 Phase 1/2 trial anticipated in 2021
- IND for third program on track to file in 2021
- Preclinical data from allogeneic TRuC-T cell program targeting mesothelin anticipated in 2021
- Preclinical data presentations from new autologous TRuC-T cell programs anticipated in 2021
CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- TCR2 TherapeuticsInc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced its strategic priorities and anticipated upcoming milestones... (weiterlesen im Link, interessant)
https://investors.tcr2.com/news-releases/...-strategic-priorities-and
https://www.tcr2.com/
33,3 Mio.Aktien.
Marktkapi heute 1 Mrd.$
Seite 7 und 8
"TRuC-T Cells Designed to Combine Best Features of CAR-T and TCR-T"
Wirklich Sinn macht der Mechanismus meines Erachtens daher erst bei universell anwendbaren T-Zellen von der Stange als Basis. Genau dies wird TCRR in zukünftigen Versionen angehen und hat als Konkurrent Adaptimmune mit deren sogenanten HiT iT-Zellen jüngst auch in seiner 5 Jahresplanung vorgestellt. Interessanterweise hat Adaptimmune ebenfalls Mesothelin als erstes Zielantigen ausgewählt und plant dieses in Zusammenarbeit mit Astellas als HLA-unabhängiges, universelles Zellprodukt an den Markt zu bringen (siehe Adaptimmune Frimenpräsentation zur JPM 2021 auf Folie 31 /32 ).
February 04, 2021 08:00 ET | Source: TCR2 Therapeutics
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- "TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the appointment of Shawn Tomasello to its Board of Directors. With more than 35 years of broad commercial and medical affairs experience in the biotechnology industry, Ms. Tomasello has successfully built and led commercial operations at several companies, including Pharmacyclics, Celgene and Genentech. Her most recent role as Chief Commercial Officer at Kite Pharma involved establishing the infrastructure for manufacture and launch of T-cell therapy Yescarta® for non-Hodgkin lymphoma..."
https://www.globenewswire.com/news-release/2021/...-of-Directors.html
at AACR Annual Meeting
April 10, 2021 08:31 ET | Source: TCR2 Therapeutics
https://www.globenewswire.com/news-release/2021/...nnual-Meeting.html
Zahlen für Q1/21
- keine Umsätze
- Verlust 21 Mio. $
- Cash 333 Mio. $
- MK 482 Mio. $
- Watchlist
- We expect cash on hand to support operations through 2023
https://investors.tcr2.com/news-releases/...er-2021-financial-results
Aug 17, 2021
https://investors.tcr2.com/news-releases/...g-medical-meetings-update
"CAMBRIDGE, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that their interim update on the Phase 1/2 clinical trial of gavo-cel will be featured in the official Press Programme at the European Society for Medical Oncology (ESMO). Additionally, due to TCR2 opting to not present its accepted featured poster presentation on September 8, 2021 at the World Conference on Lung Cancer (WCLC), the Company was notified by the WCLC of their decision to withdraw its abstract titled “Phase 1 Trial of Gavocabtagene Autoleucel (gavo-cel, TC-210) In Refractory Mesothelin-Expressing Solid Tumors.”
The Company will highlight all of its new clinical data from the dose escalation portion of the Phase 1/2 clinical trial of gavo-cel in patients with refractory mesothelin-expressing solid tumors as part of an oral presentation at the ESMO Congress 2021 on September 17 at 14:20 CEST (8:20am EST). The presentation will include clinical and translational data from at least 17 evaluable patients treated with gavo-cel up to dose level 5 (DL5). In addition to malignant mesothelioma and ovarian cancer, the presentation will include data from a third mesothelin-expressing solid tumor indication, cholangiocarcinoma.
“We look forward to reviewing the full dataset in our oral presentation at ESMO where we can thoroughly discuss the compelling results of gavo-cel in now three different solid tumor indications. We believe this data set, focusing on consistency in tumor regression, disease control and improvement in overall survival, will help determine whether gavo-cel as a monotherapy is the most promising mesothelin-directed therapy in the clinic,” said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics.
Title: Phase 1 Trial of Gavocabtagene Autoleucel (gavo-cel, TC-210) In Refractory Mesothelin-Expressing Solid Tumors
Presentation: #959O
Speaker: David S. Hong, MD Anderson Cancer Center
Session: Investigational Immunotherapy"
TCR2 Therapeutics Shares Drop 32% After Results for Solid Tumor Treatment
Published: Sept. 17, 2021 at 10:35 a.m. ET
By Chris Wack
https://www.marketwatch.com/story/...lid-tumor-treatment-271631889310
"TCR2 Therapeutics Inc. shares fell 32% to $10.65 after the company reported interim results from the ongoing Phase 1 portion of its gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors.
The company said the overall response rate was 31% in patients infused with gavo-cel following lymphodepletion.
The company said that as of the June 30 data cutoff, 17 patients had received a single gavo-cel infusion in the dose escalation portion of the gavo-cel Phase 1 clinical trial.
The median number of prior lines of therapy was 5, including immune checkpoint inhibitors and mesothelin-directed therapies. Two dose limiting toxicities were reported: one Grade 3 pneumonitis at DL1 that resolved with supportive measures, which permitted the continuation of dose escalation, and one Grade 5 bronchoalveolar hemorrhage at DL5, which along with the development of severe CRS in all 3 patients treated at this dose level.
TCR2 said 15 of the 16 patients evaluable for efficacy experienced regression of their target lesions, ranging in magnitude from 5% to 75%. Six patients achieved partial responses by target lesion assessment, four of whom achieved a partial resonse. The median overall survival for patients with mesothelioma is 11.2 months, whereas the median progression free survival is 5.9 months......"
-
Derzeit -30%
https://www.nasdaq.com/market-activity/stocks/tcrr/real-time
Zahlen für Q2/21
- keine Umsätze
- Verlust 24 Mio. $
- Cash 317 Mio. $
- MK 411 Mio. $
We expect cash on hand to support operations through 2023
https://investors.tcr2.com/news-releases/...er-2021-financial-results
Zahlen sehen gut aus. Ob die Studiendaten diesen Abschlag rechtfertigen ziehe ich in Zweifel.
https://investors.tcr2.com/news-releases/...e-interim-results-ongoing
Okay, hab mir die Daten jetzt doch noch mal genauer angeschaut und habe einige Punkte gefunden:
- "nur" 25% ORR (bei unabhängiger Prüfung)
- möglicherweise problematische Toxiditäten (Grad 5) in höheren Dosen
Das könnte darauf hindeuten, dass solide Tumore (bei dieser Behandlung) mit CART/TCRT schwer zu erreichen sind und NK-basierte Behandlungen (momentan) vielversprechender Aussehen.
Überlege jetzt auch einzusteigen.
Buy Rating von HCW
https://www.tipranks.com/news/blurbs/...eutics-tcrr?mod=mw_quote_news
Geschäftsquartal Q2 2021, abgelaufen am 30.06.21.
§Veränderung im Jahresvergleich
Umsatz
--
Nettogewinn§
§-24,31 Mio.
-49,66 %
Verwässerte EPS - -
Nettoumsatzrendite - - §
Betriebsergebnis§-24,29 Mio.
-45,33 %
Zahlungswirksame Veränderung des Finanzmittelbestands 30,52 Mio.
64,05 %
Zahlungsmittelbestand§248,79 Mio.
400,64 %
Umsatzkosten - -§
Das Unternehmer ist seit 2015 unterwegs uns macht keinen Umsatz.....
Jährlich ein Minus von ca 25 Millionen
da Frage ich mich so lange die keine einnahmen haben und immer weiter Geld verbrennen wieso sollte ich hier einsteigen??
Weil die Aktie tief gefallen ist,wenn alleine deswegen ,dann gehe ich lieber in Casino da weiss ich mindestens was ich mache ;-)
Es müssen einnahmen hier,sonst wird es NIX........
Hart aber fair ;-)
15.03.2019 17:04
TCR2 Therapeutics Outperform (BMO Capital Markets)
TCR2 Therapeutics Inc Registered Shs
TCR2 Therapeutics Chart
Charts
News
Analysen
Hier für 0 € handeln
Der Analyst BMO Capital Markets hat die Einstufung für TCR2 Therapeutics Inc Registered Shs auf "Outperform" mit einem Kursziel von 37 USD belassen.
Wo die Aktie am 15.03.2019 mit 37 USD bewertet wurde kostete die Aktie genau 15.79 Euro,
Danach am 13.03.2020 6.1 EURO
und höchsstand 15.01.2021 27.40 Euro...
Leute macht euch von Analysten bitte nicht verrückt
In dem Sinne viel Glück........
Alles im Leben hat sein grund ,ich persönlich werde um die 5 Euro vielleicht eine kleine Position baun.....
Erst schweiß, oder Brötchen danach Geld....Das Brötchen muss erst gebacken werden ;-)
Bin am 23.9. mit einer ersten Postion eingestiegen.
Alert ausgelöst
- MK 291 Mio. $ müsste jetzt in etwa auf dem Cashbestand nach Q3/21 liegen
- Börsenbewertung = Cash + Pipeline "gratis" dazu
R&D Day: Pipeline & Strategie
https://investors.tcr2.com/news-releases/...eline-and-strategy-rd-day
MK 274 Mio. $, einige vermuten, dass hier ein Institutioneller seine Anteile reduzieren könnte.
TCR² Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo® and Yervoy® in Mesothelin-Expressing Solid Tumors
Published: Oct 25, 2021
CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced a clinical trial collaboration agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate gavo-cel in combination with Opdivo® (nivolumab) and Yervoy® (ipilimumab) in its planned Phase 2 clinical trial in treatment refractory mesothelin-expressing solid tumors. The primary objective of the Phase 2 trial is to evaluate the efficacy of gavo-cel in patients with unresectable, metastatic or recurrent mesothelin-expressing cancers including non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma (MPM) and cholangiocarcinoma. TCR2 is sponsoring the Phase 2 trial...
Zahlen für Q3/21
- keine Umsätze
- Verlust 26 Mio. $
- Cash 296 Mio. $
- MK 227 Mio. $
https://investors.tcr2.com/news-releases/...er-2021-financial-results